Molecular Pharmacology Program
The David Scheinberg Lab
Research

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials (Blood, 2010), and a vaccine to WT1 in Phase III trials. Read full article in Science.
We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013), (Nature Biotech., 2015), as well as prototype targeted nano-machines (Nature Nano, 2013).
Research Projects

Featured News
Publications
People

David A. Scheinberg, MD, PhD
Chair, Molecular Pharmacology Program, SKI; Director, Center for Experimental Therapeutics, MSK
- Molecular Pharmacology Program Chair David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
- MD, PhD, Johns Hopkins University School of Medicine
- scheinbd@mskcc.org
- Email Address
- 646-888-2190
- Office Phone
- View physician profile
- Physician profile
Members


- Ph.D in Immunology from Hyogo College of Medicine, Japan (1990)
- MD in Medicine from Medical School of Inner Mongolia (1982)


- PhD in Chemistry from Case Western Reserve University in Cleveland, Ohio (1985)
- ME in Chemical Engineering from The City University of New York (2004)

- BS in Biophysics from Humboldt University in Berlin (2018)
- MS in Biomedical Sciences from UCL London (2019)

- BA in Biology from Swarthmore College, Swarthmore, PA (2017)


- BS in Biomedical Engineering from Boston University (2016)

- PhD in Oncology from A. C. Camargo Hospital, Sao Paulo, BR
- and from MD Anderson Cancer Center, Texas US (2009)


- MD from Eberhard Karls University in Tuebingen, Germany (2014)

- BS in Pharmacology , and MA in Molecular Biology from the University of California, Santa Barbara

- PhD in Immunology from Heinrich Heine University, Germany (2015)

- BS in Biology from St. John' s University in Queens, NY (2017)

- PhD in Chemistry from Tufts University (2018)
- BS in Biochemistry from Hobart and William Smith Colleges (2013)

- MD in Internal Medicine from Sechenov (1st) Moscow Medical Institute, Moscow, Russia,(1990)
- PhD in Medical Science, from State Scientific Center of Russian Federation Institute of Biophysics, Moscow, Russia,(1997)

- BS in Biomedical Engineering from UC San Diego, CA (2012)
- MEng. in Biomedical Engineering from Cornell University (2013)
- 646-888-2205
- Lab Phone

- BS in Chemistry from The College of New Jersey, Ewing NJ (2019)

Senior Research Technician

Senior Research Scientist

Senior Research Technician

Member and Attending

Graduate Student

Graduate Student

Research Technician

Graduate Student

Research Assistant

Graduate Student

Research Fellow

Graduate Student

Research Associate

Senior Research Technician

Research Scholar

Senior Research Scientist

Graduate Student

Graduate Student

- BS, Cornell University



Lab Alumni

Principal Scientific Communication Lead at Genentech, San Francisco, CA

Graduate Student


Research Fellow

Graduate Student
Graduate Student

Visiting Scientist
Graduate Student
Research Technician
Graduate Student
Graduate Student
Graduate Student
Graduate Student

Research Technician

Research Technician

Lab Rotation SEP-DEC 2020

Research Technician

Research Fellow
Lab Affilations
- Molecular Pharmacology Program
- Department of Medicine
- Center for Experimental Therapeutics
- Center for Cell Engineering
- Geoffrey Beene Cancer Research Center
- Center for Molecular Imaging & Nanotechnology
- Tri-Institutional PhD Program in Chemical Biology
- Gerstner Sloan Kettering Graduate School of Biomedical Sciences
Lab News & Events
Journal Club & Photo AlbumGet in Touch
-
Lab Head Email
-
Office Phone
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
David A. Scheinberg discloses the following relationships and financial interests:
-
Actinium
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services -
Arvinas, Inc
Ownership / Equity Interests -
Bridge Medicines
Provision of Services (uncompensated) -
ContraFect
Ownership / Equity Interests -
Ensysce Bioscience
Ownership / Equity Interests -
Eureka Therapeutics Inc
Ownership / Equity Interests; Provision of Services (uncompensated) -
Great Point Partners
Ownership / Equity Interests; Provision of Services -
Iovance Biotherapeutics, Inc.
Ownership / Equity Interests
-
KLUS Pharma, Inc
Provision of Services -
Lantheus Medical Imaging, Inc.
Ownership / Equity Interests -
OncoPep, Inc.
Provision of Services -
Pfizer, Inc.
Ownership / Equity Interests; Provision of Services -
Progenics Pharmaceuticals, Inc.
Provision of Services (uncompensated) -
Sapience Therapeutics, Inc.
Fiduciary Role/Position; Ownership / Equity Interests -
Sellas Life Science Group
Fiduciary Role/Position; Intellectual Property Rights; Ownership / Equity Interests
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.